HLB "Lenvatinib, a Promising Treatment for Lung Cancer... US Paper Published"

[Asia Economy Reporter Hyunseok Yoo] HL Biopharma announced on the 24th that the results of combination therapy with rivoceranib (Chinese name Apatinib) and vinorelbine for wild type non-small cell lung cancer (NSCLC) patients without standard treatment were published in a paper in JAMA Network Open, a journal published by the American Medical Association.

In a Phase 2 investigator-initiated study conducted at Central South University in Hunan Province, China, the combination of rivoceranib and vinorelbine showed significant efficacy with a disease control rate (DCR) of 76.7%, objective response rate (ORR) of 36.7%, median progression-free survival (mPFS) of 4.5 months, and median overall survival (mOS) of 10 months.

The paper stated, “Oral Apatinib combined with oral vinorelbine demonstrated excellent efficacy as a third-line treatment for NSCLC patients without genetic mutations, and the toxicity was manageable, making it a very promising treatment option.”

Recently, Hansoh Pharmaceutical decided to advance Phase 3 commercialization clinical trials for rivoceranib combined with Gefitinib, an epidermal growth factor receptor (EGFR) target, as first-line treatment for NSCLC, and rivoceranib combined with Camrelizumab, a PD-1 target, respectively.

Worldwide, lung cancer ranks first in both incidence and mortality among cancers. The high mortality rate of lung cancer is due to the absence of early symptoms. Lung cancer is classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with over 80% of lung cancer patients diagnosed with NSCLC.

Recently, upon diagnosis of NSCLC, treatment methods are determined through genetic testing for mutations such as epidermal growth factor receptor (EGFR). However, for advanced NSCLC patients without genetic mutations, standard treatment is lacking after receiving second-line or later cytotoxic chemotherapy.

An HL Biopharma official stated, “Lung cancer treatment is subdivided according to biomarkers such as EGFR, ALK, ROS1, and PD-L1, and rivoceranib’s advantage as a drug that can be used as a basis for combination therapy with various targeted drugs has been reconfirmed.”

Last month, HL Biopharma signed a contract to acquire global rights, including China, for rivoceranib from Advenchen. Following Hansoh Pharmaceutical’s recent application for marketing approval of rivoceranib as a second-line treatment for liver cancer in China, various indications such as Phase 3 lung cancer clinical trials are being pursued, raising expectations for increased royalty revenue for HL Biopharma.

This content was produced with the assistance of AI translation services.